Incyte's (INCY) Jakafi Granted FDA Orphan Drug Designation in Graft Versus Host Disease
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Incyte (NASDAQ: INCY) Jakafi was granted FDA orphan drug designation in Graft Versus Host Disease.
|Orphan Designation:||Treatment of graft versus host disease|
|Orphan Designation Status:||Designated|
|FDA Orphan Approval Status:||Not FDA Approved for Orphan Indication|
|Marketing Approval Date:||N/A|
|Approved Labeled Indication:|
|Exclusivity End Date:||N/A|
1801 Augustine Cut-Off
Wilmington, Delaware 19803
The sponsor address listed is the last reported by the sponsor to OOPD.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Eli Lilly & Co. (LLY), Incyte (INCY) Announce FDA Extends Review Period for Baricitinib
- Teva Pharma (TEVA) Announces FDA Approval for VANTRELATM ER with Abuse Deterrence Technology
- McKesson in record $150 million U.S. settlement over suspicious drug orders
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!